



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/147918/>

Version: Accepted Version

---

**Article:**

Huang, K, Parmeggiani, F, Ledru, H et al. (2019) Enzymatic synthesis of N-acetyllactosamine from lactose enabled by recombinant  $\beta$ 1,4-galactosyltransferases. *Organic and Biomolecular Chemistry*, 17 (24). pp. 5920-5924. ISSN: 1477-0520

<https://doi.org/10.1039/C9OB01089K>

---

© The Royal Society of Chemistry 2019. This is an author produced version of a paper published in *Organic and Biomolecular Chemistry*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

## COMMUNICATION

Enzymatic synthesis of *N*-acetylglucosamine from lactose enabled by recombinant  $\beta$ 1,4-galactosyltransferases

Received 00th January 20xx,  
Accepted 00th January 20xx


DOI: 10.1039/x0xx00000x

Kun Huang,<sup>a</sup> Fabio Parmeggiani,<sup>a</sup> Helene Ledru,<sup>b</sup> Kristian Hollingsworth,<sup>c</sup> Jordi Mas Pons,<sup>b</sup> Andrea Marchesi,<sup>a</sup> Peter Both,<sup>a</sup> Ashley P. Matthey,<sup>a</sup> Edward Pallister,<sup>a</sup> Gregory S. Bulmer,<sup>a</sup> Jolanda M. van Munster,<sup>a</sup> W. Bruce Turnbull,<sup>c</sup> M. Carmen Galan,<sup>\*b</sup> Sabine L. Flitsch<sup>\*a</sup>

Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial  $\beta$ 1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to *N*-acetylglucosamine to form *N*-acetylglucosamine in the presence of UDP. The process is demonstrated by the preparative scale synthesis of *p*NP- $\beta$ -LacNAc from lactose using  $\beta$ 1,4-galactosyltransferase NmLgtB-B as the only biocatalyst.

Galactosides are among the most abundant glycans in the mammalian glycome and are generally biosynthesised by Leloir galactosyltransferases. In particular, *N*-acetylglucosamine (LacNAc) is a common core glycan motif (e.g., Type 2 glycans) in free oligosaccharides, glycoproteins and glycolipids. Galactosides, including LacNAc, are important constituents of human milk oligosaccharides, which have great health benefits for infants.<sup>1,2</sup> Sialylated and fucosylated LacNAc such as sialyl Lewis<sup>x</sup> have been described as ligands of various lectins, such as selectins.<sup>3</sup> The demand of galactosides for biological investigation and commercialisation as additives to formula milk has increased considerably over the last decade and synthetic methods employing biocatalysts are very attractive compared to multi-step chemical strategies.<sup>4–10</sup>

The central role of galactosides in these bioactive oligosaccharides, in particular LacNAc (**1**), has prompted the development of several enzymatic synthetic strategies (Scheme 1). Key to all is the activation of the galactose



**Scheme 1.** Enzymatic approaches for LacNAc derivative (**1**) synthesis using GlcNAc-R as acceptor and **2–5** as donor substrates.

anomeric centre, since direct glycosidic bond formation from free reducing sugars is unfavourable. In biosynthesis, UDP-galactose (**2**) is commonly utilised as the activated substrate by a wide range of galactosyltransferases, but the cost of this substrate can be prohibitive in large scale synthesis.

Several elegant alternative synthetic approaches have been developed using activated substrates such as galactosyl fluoride (**3**)<sup>11</sup> and *p*NP-galactose (**4**).<sup>12</sup> UDP-galactose (**2**) can also be regenerated using a multienzyme system from either galactose or sucrose, which adds additional steps and potential side-products.<sup>13–15</sup> It has been recognised that the most cost-efficient galactosyl donor would be lactose (**5**), a waste product of the cheese industry that is produced at >6 million ton scale every year. So far, the use of lactose as substrate has been limited to galactosidases, which have some inherent transgalactosylation activity, but show generally poor regioselectivity and low yield.<sup>16,17</sup>

<sup>a</sup> Manchester Institute of Biotechnology (MIB), School of Chemistry, The University of Manchester, 131 Princess Street, M1 7DN, Manchester, United Kingdom. E-mail: sabine.flitsch@manchester.ac.uk

<sup>b</sup> School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, United Kingdom. E-mail: m.c.galan@bristol.ac.uk


<sup>c</sup> School of Chemistry and Asbury Centre for Structural Molecular Biology, The University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, United Kingdom.

Electronic Supplementary Information (ESI) available: experimental section, procedures for chemical synthesis and enzymatic assays, representative MALDI traces, and copies of NMR and HRMS spectra. See DOI: 10.1039/x0xx00000x


These findings prompted us to look for biocatalysts that would be able to generate the donor UDP-galactose (**2**) directly *in situ* from lactose and UDP without any further cofactor. In general, Leloir glycosyltransferases are perceived to catalyse unidirectional reactions.<sup>18</sup> However, the reversible catalytic activity of natural product glycosyltransferases has been described,<sup>19</sup> and subsequently employed to synthesise a wealth of different nucleotide sugars in the presence of nucleotides.<sup>20</sup> Leloir glycosyltransferases such as sucrose synthase<sup>21</sup> and  $\alpha$ , $\alpha$ -trehalose synthase<sup>22</sup> were widely used to produce nucleotide diphosphate glucose based on its reversible activity. Furthermore, mammalian sialyltransferase ST3Gal-II was used to synthesise CMP-Neu5Ac from  $\alpha$ 2,3 sialylated glycans and glycoconjugates in the presence of CMP,<sup>23</sup> which was utilised to label sialic acid containing glycoproteins and gangliosides.<sup>24</sup> Recently, two bacterial  $\alpha$ 2,6-sialyltransferases were exploited as specific  $\alpha$ 2,6-sialidases based on their reverse activity.<sup>25,26</sup> Furthermore, glycosyl transfer catalysed by  $\beta$ 1,4-*N*-acetylglucosaminyltransferase III (GnT-III) was also reversible.<sup>27</sup> However, to the best of our knowledge there is no report on galactosyltransferases exhibiting reverse transfer from lactose.

For the initial screening of transgalactosylation activity, it was important to develop a fast and robust assay that would detect even weak galactose transfer activity in the presence of a high excess of lactose. Our previous work had shown that sugar acceptors tagged with imidazolium-based probes (I-Tags) allow for the monitoring of glycosylation reactions by mass spectrometry (MALDI-ToF),<sup>28–31</sup> even in complex mixtures.<sup>32</sup> The cationic I-Tag generates a strong MS signal that dominates the ionisation of the analytes<sup>31</sup> and allows for a reasonable estimate of overall yields by measurement of starting material and product peaks.

For the purpose of the present study, a new class of benzyl carbamate-containing I-Tagged glucosides of Glc (**11**) and GlcNAc (**12**) were chemically synthesised from 1-azidopropyl derivatives **6a**<sup>33</sup> and **6b**<sup>30</sup> in 4 steps, giving 18% and 21% overall yield respectively (Scheme 2, see ESI for further details). As expected, MALDI-ToF spectra of Glc-I-Tag (**11**) and GlcNAc-I-Tag (**12**) provided strong peaks with expected mass in aqueous and buffer solutions (Figure 1). Furthermore, when both I-Tagged substrates were treated with a galactosyltransferase (NmLgtB-A, see below) and UDP-Gal (**2**) the glycosylation products could be clearly observed by MALDI-ToF without any further purification (Figure 1), providing an excellent basis for further screening studies.



**Scheme 2.** Chemical synthesis of Glc-I-Tag (**11**) and GlcNAc-I-Tag (**12**).




**Figure 1.** MALDI-ToF mass spectra of I-Tag substrates (**11** and **12**, blue traces) and their biotransformation products (**13** and **14**, red traces). Glc-I-Tag **11** [M]<sup>+</sup> = 466, GlcNAc-I-Tag **12** [M]<sup>+</sup> = 507, Lac-I-Tag **13** [M]<sup>+</sup> = 628, and LacNAc-I-Tag **14** [M]<sup>+</sup> = 669.

The I-Tag methodology was next used to screen galactosyltransferase activity from lactose (**5**) instead of UDP-Gal (**2**). Three bacterial  $\beta$ 1,4-galactosyltransferases were cloned from *Neisseria meningitidis* serogroup A strain Z2491 (NmLgtB-A), *Neisseria meningitidis* serogroup B strain MC58 (NmLgtB-B)<sup>8</sup> and *Neisseria meningitidis* (NmLgtH). NmLgtB-A and NmLgtB-B are homologous proteins from different strains (92% identity), while NmLgtH shows 71% and 72% identity to NmLgtB-A and NmLgtB-B, respectively,

as shown by the amino acid sequence alignment (ESI, Figure S2). All three proteins were produced recombinantly in *E. coli* BL21 (DE3) with an N-terminal His<sub>6</sub>-tag, and purified by affinity chromatography. In the first instance, the activity of the three  $\beta$ 1,4-galactosyltransferases was confirmed by using Glc-I-Tag (**11**) and GlcNAc-I-Tag (**12**) as substrates (Scheme 3A), although LgtH displayed only low activity against **12** (data not shown).

Having established a sensitive MS-based assay on I-Tagged substrates, lactose (**5**) was tested as galactose donor in the presence of UDP (Scheme 3B). Given that the equilibrium between lactose and UDP-Gal would be expected to be unfavourable towards the latter, UDP-Gal generation was monitored by coupling the reactions with subsequent galactose transfer to the I-Tagged acceptor substrates **11** and **12** (Scheme 3), which would result in transfer of galactose from lactose to substrate *via in situ* formation of UDP-Gal. Rewardingly, formation of Lac-I-Tag (**13**) and LacNAc-I-Tag (**14**) from **11** and **12** (Scheme 3) could be detected by MALDI-ToF spectrometry in the NmLgtB-B catalysed reactions, while NmLgtB-A afforded only a very low conversion and NmLgtH no conversion at all (ESI, Figures S3-S8). Therefore, NmLgtB-B was used in all subsequent experiments.




**Scheme 3.** Investigation of galactosyltransferase activity with I-Tag acceptor substrates **11** and **12**. A: using UDP-Gal (**2**) as sugar donor. B: using lactose (**5**) as sugar donor.

The scope of galactose donor substrates beyond lactose was also tested using *p*NP- $\beta$ -Lac, *p*NP- $\alpha$ -Gal, *p*NP- $\beta$ -Gal and LacNAc (**1**) as galactose donors in the presence of UDP. Galactose transfer was also observed in reactions containing *p*NP- $\beta$ -Lac and LacNAc (ESI, Figures S9-S10). However, since lactose (**5**) is inexpensive and easily available, it was subsequently used as a preferable galactose donor.

The optimal reaction conditions for the transgalactosylation activity of NmLgtB-B were explored by studying the effects of pH, UDP concentration and lactose concentration on the yield, using *p*NP- $\beta$ -GlcNAc (**15**) as acceptor (Figure 2). Interestingly, with NmLgtB-B higher


conversions could be achieved in acidic environment, with a maximum around pH 5.0 (Figure 2A). This could potentially be ascribed to the pH-dependent protonation of the beta-phosphate group in UDP, as previously observed for sucrose synthase.<sup>21,34</sup> In the absence of UDP no conversion was observed, suggesting that UDP is required for the transfer reaction and providing the first mechanistic clue that the reactions would proceed *via* UDP-Gal (**2**). Product formation increased gradually when the concentration of UDP was increased, with a plateau reached at 2 mM (Figure 2B). Screening of different lactose (**5**) concentrations established that no significant increases in the conversion could be achieved above 20 mM (Figure 2C).



**Figure 2.** Optimisation of the transgalactosylation reaction conditions. A: pH dependence, using 1 mM *p*NP- $\beta$ -GlcNAc, 5 mM UDP and 10 mM Lac. B: UDP conc. dependence, using 1 mM *p*NP- $\beta$ -GlcNAc, 10 mM Lac and sodium acetate (SA) buffer pH 5.0. C: lactose (**5**) conc. dependence, using 1 mM *p*NP- $\beta$ -GlcNAc, 2mM UDP and sodium acetate (SA) buffer pH 5.0.

The formation of UDP-Gal (**2**) as an intermediate was also verified directly by HRMS analysis of the crude incubation mixture. In a reaction mixture containing lactose (**5**), UDP and NmLgtB-B in acetate buffer pH 5.0 incubated at 37°C overnight, it was possible to detect the presence of UDP-Gal (**2**), while a negative control without enzyme did not show the diagnostic peaks (ESI, Figure S11).

The practical application of galactosylation from lactose (**5**) was demonstrated by the preparative synthesis of *p*NP- $\beta$ -LacNAc (**16**) (Scheme 4). Initially, a reaction time course was carried out to monitor the reaction process. No significant product increase was observed after 7 h incubation at 37°C (ESI, Figure S12). Hence, preparative scale reaction mixture containing *p*NP- $\beta$ -GlcNAc (**15**, 51  $\mu$ mol), lactose (**5**, 1 mmol) and UDP (112  $\mu$ mol) were incubated with NmLgtB-B at 37°C for 14 h, affording 90% conversion as measured by HPLC (ESI, Figure S13). The unreacted *p*NP- $\beta$ -GlcNAc (**15**) was removed by hydrolysis with  $\beta$ -*N*-acetylhexosaminidase, which allowed for the product to be isolated by preparative reverse-phase HPLC, yielding *p*NP- $\beta$ -LacNAc (**16**) in 50% overall yield.



**Scheme 4.** Preparative synthesis of *p*NP- $\beta$ -LacNAc (**16**).

## Conclusions

The reversibility of the catalytic activity of Leloir  $\beta$ 1,4-galactosyltransferases, in particular NmLgtB-B, was demonstrated for the first time by utilising novel imidazolium-tagged substrates. This reversibility allowed for the *in situ* formation of UDP-Gal (**2**) from inexpensive lactose (**5**), in the presence of UDP. By adding a further acceptor substrate the overall transfer of galactose from lactose (**5**) to acceptor substrates **11**, **12** and **15** could be observed. The practical applicability of this simple transgalactosylation method was demonstrated by preparative scale synthesis of *p*NP- $\beta$ -LacNAc (**16**) from lactose using NmLgtB-B as the only biocatalyst. The excess of lactose drives the reaction in the direction of the formation of **16** efficiently and without side-products. Even though a large excess of lactose and overstoichiometric UDP are required, lactose is a waste

product of the milk industry and UDP is considerably less expensive than the LacNAc derivatives obtained. Therefore, our transglycosylation strategy could potentially provide an opportunity for converting bio-waste into products with higher added value.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This study was funded by the BBSRC, EPSRC and InnovateUK: IBCatalyst programme [BB/M029034/1, BB/M028836/1 (SLF), BB/M028976/1 (MCG), BB/PO11462/1 (JvM), BB/M028747/1 (WBT)], Marie Skłodowska-Curie Innovative Training Network [H2020-MSCA-ITN-2014-ETN-642870] and the European Research Council (ERC) COG: 648239 (to MCG) and ProgrES-DVL-788231 (to SLF). We are grateful for the help provided by Dr. Reynard Spiess and Dr. Matt Cliff for HRMS and NMR analyses, respectively.

## Notes and references

- 1 B. Petschacher and B. Nidetzky, *J. Biotechnol.*, 2016, **235**, 61–83.
- 2 Y. Vandenplas, B. Berger, V. P. Carnielli, J. Ksiazek, H. Lagström, M. S. Luna, N. Migacheva, J. M. Mosselmans, J. C. Picaud, M. Possner, A. Singhal and M. Wabitsch, *Nutrients*, DOI:10.3390/nu10091161.
- 3 L. A. Lasky, *Annu. Rev. Biochem.*, 1995, **64**, 113–140.
- 4 R. Šardžik, A. P. Green, N. Laurent, P. Both, C. Fontana, J. Voglmeir, M. J. Weissenborn, R. Haddoub, P. Grassi, S. M. Haslam, G. Widmalm and S. L. Flitsch, *J. Am. Chem. Soc.*, 2012, **134**, 4521–4524.
- 5 Z. Wang, Z. S. Chinoy, S. G. Ambre, W. Peng, R. McBride, R. P. De Vries, J. Glushka, J. C. Paulson and G. Boons, *Science (80- )*, 2013, **341**, 379–384.
- 6 S. S. Shivatare, S. H. Chang, T. I. Tsai, S. Y. Tseng, V. S. Shivatare, Y. S. Lin, Y. Y. Cheng, C. T. Ren, C. C. D. Lee, S. Pawar, C. S. Tsai, H. W. Shih, Y. F. Zeng, C. H. Liang, P. D. Kwong, D. R. Burton, C. Y. Wu and C. H. Wong, *Nat. Chem.*, 2016, **8**, 338–346.
- 7 Z. Wu, Y. Liu, C. Ma, L. Li, J. Bai, L. Byrd-Leotis, Y. Lasanajak, Y. Guo, L. Wen, H. Zhu, J. Song, Y. Li, D. A. Steinhauer, D. F. Smith, B. Zhao, X. Chen, W. Guan and P. G. Wang, *Org. Biomol. Chem.*, 2016, **14**, 11106–11116.
- 8 K. Lau, V. Thon, H. Yu, L. Ding, Y. Chen, M. M. Muthana, D. Wong, R. Huang and X. Chen, *Chem. Commun.*, 2010, **46**, 6066–6068.
- 9 H. Kunz, J. C. Paulson and C. Unverzagt, *J. Am. Chem. Soc.*, 1990, **112**, 9308–9309.
- 10 A. Cabanettes, L. Perkams, C. Spiess, C. Unverzagt and A.

- Varrot, *Angew. Chem. Int. Ed. Angew. Chem*, 2018, **10**, 10178–10181.
- 11 C. Mayer, D. L. Zechel, S. P. Reid, R. A. J. Warren and S. G. Withers, *FEBS Lett.*, 2000, **466**, 40–44.
- 12 M. J. Hernaiz and D. H. G. Crout, *J. Mol. Catal. - B Enzym.*, 2000, **10**, 403–408.
- 13 C. H. Wong, R. Wang and Y. Ichikawa, *J. Org. Chem.*, 1992, **57**, 4343–4344.
- 14 A. Zervosen and L. Elling, *J. Am. Chem. Soc.*, 1996, **118**, 1836–1840.
- 15 M. M. Muthana, J. Qu, Y. Li, L. Zhang, H. Yu, L. Ding, H. Malekan and X. Chen, *Chem. Commun.*, 2012, **48**, 2728–2730.
- 16 Y. Ishido, H. Ohi and T. Usui, *J. Carbohydr. Chem.*, 1992, **11**, 553–565.
- 17 N. Kaftzik, P. Wasserscheid and U. Kragl, *Org. Process Res. Dev.*, 2002, **6**, 553–557.
- 18 K. M. Koeller and C. H. Wong, *Glycobiology*, 2000, **10**, 1157–1169.
- 19 G. Reactions, C. Zhang, B. R. Griffith, Q. Fu, C. Albermann, X. Fu, I. Lee, L. Li and J. S. Thorson, 2006, **313**, 1291–1295.
- 20 R. W. Gantt, P. Peltier-Pain, S. Singh, M. Zhou and J. S. Thorson, *Proc. Natl. Acad. Sci.*, 2013, **110**, 7648–7653.
- 21 A. Gutmann and B. Nidetzky, *Adv. Synth. Catal.*, 2016, **358**, 3600–3609.
- 22 S. I. Ryu, J. E. Kim, E. J. Kim, S. K. Chung and S. B. Lee, *Process Biochem.*, 2011, **46**, 128–134.
- 23 E. V. Chandrasekaran, J. Xue, J. Xia, R. D. Locke, K. L. Matta and S. Neelamegham, *Biochemistry*, 2008, **47**, 320–330.
- 24 E. V. Chandrasekaran, J. Xue, J. Xia, R. D. Locke, S. A. Patil, S. Neelamegham and K. L. Matta, *Biochemistry*, 2011, **50**, 9475–9487.
- 25 J. B. McArthur, H. Yu, N. Tasnima, C. M. Lee, A. J. Fisher and X. Chen, *ACS Chem. Biol.*, 2018, **13**, 1228–1234.
- 26 P. Both, M. Riese, C. J. Gray, K. Huang, E. G. Pallister, I. Kosov, L. P. Conway, J. Voglmeir and S. L. Flitsch, *Glycobiology*, 2018, **28**, 261–268.
- 27 T. Okada, H. Ihara, R. Ito, N. Taniguchi and Y. Ikeda, *Glycobiology*, 2009, **19**, 368–374.
- 28 M. C. Galan, A. T. Tran, K. Bromfield, S. Rabbani and B. Ernst, *Org. Biomol. Chem.*, 2012, **10**, 7091–7097.
- 29 I. Sittel and M. C. Galan, *Bioorganic Med. Chem. Lett.*, 2015, **25**, 4329–4332.
- 30 M. C. Galan, A. T. Tran and C. Bernard, *Chem. Commun.*, 2010, **46**, 8968–8970.
- 31 M. C. Galan, R. A. Jones and A. T. Tran, *Carbohydr. Res.*, 2013, **375**, 35–46.
- 32 I. Sittel and M. C. Galan, *Org. Biomol. Chem.*, 2017, **15**, 3575–3579.
- 33 C. He, S. Wang, M. Liu, C. Zhao, S. Xiang and Y. Zeng, *Org. Biomol. Chem.*, 2016, **14**, 1611–1622.
- 34 B. Nidetzky, A. Gutmann and C. Zhong, *ACS Catal.*, 2018, **8**, 6283–6300.